2,630 Shares in IDEXX Laboratories, Inc. $IDXX Bought by AlphaGrep UK Ltd

Key Points

• AlphaGrep UK Ltd. acquired 2,630 shares of IDEXX Laboratories during the second quarter, worth approximately $1.385 million and representing about 0.4% of its portfolio.
• Institutional investors own approximately 87.84% of IDEXX’s stock, while analysts maintain a “Moderate Buy” consensus with an average price target of $747.
• IDEXX exceeded quarterly expectations, reporting $4.27 in EPS and $1.22 billion in revenue; revenue rose 9.7% year over year, and the company issued fiscal 2026 EPS guidance of $14.69–$14.94.

AlphaGrep UK Ltd purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,630 shares of the company's stock, valued at approximately $1,385,000. IDEXX Laboratories makes up approximately 0.4% of AlphaGrep UK Ltd's investment portfolio, making the stock its 11th largest holding.

Several other large investors have also recently bought and sold shares of IDXX. Harbour Investments Inc. raised its position in IDEXX Laboratories by 13.3% in the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company's stock valued at $92,000 after purchasing an additional 16 shares during the last quarter. Pinnacle Associates Ltd. increased its position in shares of IDEXX Laboratories by 1.5% in the fourth quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company's stock valued at $830,000 after buying an additional 18 shares in the last quarter. Triad Wealth Partners LLC increased its holdings in IDEXX Laboratories by 3.1% during the 1st quarter. Triad Wealth Partners LLC now owns 600 shares of the company's stock valued at $337,000 after acquiring an additional 18 shares in the last quarter. Advisory Services Network LLC raised its position in IDEXX Laboratories by 2.5% during the fourth quarter. Advisory Services Network LLC now owns 752 shares of the company's stock worth $509,000 after acquiring an additional 18 shares during the last quarter. Finally, KCM Investment Advisors LLC grew its position in shares of IDEXX Laboratories by 5.3% in the fourth quarter. KCM Investment Advisors LLC now owns 377 shares of the company's stock valued at $255,000 after purchasing an additional 19 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on IDXX shares. Barclays dropped their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a research note on Tuesday, August 11th. UBS Group raised their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Citigroup lifted their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Weiss Ratings downgraded shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research note on Thursday, August 27th. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $747.00.

IDEXX Laboratories Trading Up 1.2%

IDEXX Laboratories stock opened at $535.38 on Friday. IDEXX Laboratories, Inc. has a 52-week low of $518.55 and a 52-week high of $769.98. The company has a market cap of $42.18 billion, a P/E ratio of 37.65, a P/E/G ratio of 2.83 and a beta of 1.54. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The business has a 50-day simple moving average of $558.27 and a two-hundred day simple moving average of $570.47.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.IDEXX Laboratories's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.